Caisse DE Depot ET Placement DU Quebec Raises Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Caisse DE Depot ET Placement DU Quebec lifted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 88.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 162,310 shares of the company's stock after acquiring an additional 76,383 shares during the period. Caisse DE Depot ET Placement DU Quebec owned approximately 0.20% of IDEXX Laboratories worth $67,105,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. United Capital Financial Advisors LLC increased its holdings in IDEXX Laboratories by 0.9% during the fourth quarter. United Capital Financial Advisors LLC now owns 2,446 shares of the company's stock worth $1,011,000 after buying an additional 22 shares during the last quarter. Cranbrook Wealth Management LLC grew its position in IDEXX Laboratories by 7.0% during the fourth quarter. Cranbrook Wealth Management LLC now owns 382 shares of the company's stock worth $158,000 after buying an additional 25 shares in the last quarter. Gabelli Funds LLC raised its stake in IDEXX Laboratories by 5.3% in the fourth quarter. Gabelli Funds LLC now owns 500 shares of the company's stock valued at $207,000 after purchasing an additional 25 shares in the last quarter. Perigon Wealth Management LLC raised its position in shares of IDEXX Laboratories by 1.8% during the 4th quarter. Perigon Wealth Management LLC now owns 1,474 shares of the company's stock valued at $632,000 after buying an additional 26 shares in the last quarter. Finally, Summit Trail Advisors LLC lifted its holdings in shares of IDEXX Laboratories by 3.3% in the 4th quarter. Summit Trail Advisors LLC now owns 810 shares of the company's stock worth $335,000 after acquiring an additional 26 shares during the last quarter. Institutional investors own 87.84% of the company's stock.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX traded up $5.69 during midday trading on Wednesday, reaching $479.40. 195,183 shares of the stock traded hands, compared to its average volume of 644,777. The stock has a market capitalization of $38.85 billion, a PE ratio of 44.88, a P/E/G ratio of 3.41 and a beta of 1.52. The company's 50 day moving average is $420.26 and its 200 day moving average is $428.49. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $548.88.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported $2.96 EPS for the quarter, beating analysts' consensus estimates of $2.93 by $0.03. IDEXX Laboratories had a net margin of 22.78% and a return on equity of 55.82%. The firm had revenue of $998.43 million during the quarter, compared to the consensus estimate of $998.25 million. During the same quarter last year, the firm earned $2.71 EPS. The firm's revenue for the quarter was up 3.6% compared to the same quarter last year. On average, equities research analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of the company's stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the transaction, the director now owns 3,061 shares of the company's stock, valued at $1,426,242.34. This represents a 49.50 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP George Fennell sold 9,986 shares of the business's stock in a transaction on Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the sale, the executive vice president now directly owns 8,176 shares of the company's stock, valued at $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.98% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

IDXX has been the topic of a number of recent research reports. Stifel Nicolaus decreased their price objective on IDEXX Laboratories from $450.00 to $420.00 and set a "hold" rating on the stock in a report on Monday, April 14th. StockNews.com lowered shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Saturday, April 12th. Bank of America raised their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a research note on Tuesday, February 4th. Morgan Stanley increased their price objective on IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a report on Monday. Finally, Piper Sandler upped their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a report on Monday, February 10th. Four research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, IDEXX Laboratories presently has a consensus rating of "Moderate Buy" and an average price target of $524.75.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.